Review Special Issues

No Reflow-phenomenon: from Current State of the Art to Future Perspectives

  • Received: 29 June 2015 Accepted: 24 November 2015 Published: 30 November 2015
  • Early and successful myocardial reperfusion with primary percutaneous coronary intervention (pPCI) is the optimal therapy for patients presenting with ST segment elevation myocardial infarction (STEMI). Despite successful epicardial reopening of the infarct related artery, myocardial perfusion may not be restored in up to 40-50% of patients. This phenomenon, referred to as no-reflow (NR), recognizes several pathogenetic components including distal atherothrombotic embolization, ischaemic injury, reperfusion damage, intramyocardial hemorrhage and individual susceptibility of coronary microcirculation. However the complexity of pathogenesis remains still unclear. Moreover, cause NR plays a crucial role in patients prognosis, accurate detection is critical and multiple novel diagnostic modalities has been recently assessed.The NR phenomenon represents a challenge in the management of STEMI patients and has recently captured a growing interest of both basic scientists and interventional cardiologists. Although relevant efforts to transfer into real world practice new therapeutic strategies, to date there is still weak evidence of clinical improvement in this setting. Several strategies of prevention and treatment of NR have been proposed in the clinical arena including pharmacological and mechanical interventions. Nevertheless, the complexity of the phenomenon makes extremely unlikely for a single therapy to be effective. Understanding the interaction between the components of this pathway, along with exploring newer and more effective agents may enable patients to be treated with the most appropriate therapy.

    Citation: Valeria Paradies, Filippo Masi, Francesco Bartolomucci, Alfredo Marchese, Armando Liso, Fabrizio Resta, Stefano Favale, Martino Pepe. No Reflow-phenomenon: from Current State of the Art to Future Perspectives[J]. AIMS Medical Science, 2015, 2(4): 374-395. doi: 10.3934/medsci.2015.4.374

    Related Papers:

    [1] Songbai Guo, Xin Yang, Zuohuan Zheng . Global dynamics of a time-delayed malaria model with asymptomatic infections and standard incidence rate. Electronic Research Archive, 2023, 31(6): 3534-3551. doi: 10.3934/era.2023179
    [2] Gaohui Fan, Ning Li . Application and analysis of a model with environmental transmission in a periodic environment. Electronic Research Archive, 2023, 31(9): 5815-5844. doi: 10.3934/era.2023296
    [3] Wenxuan Li, Suli Liu . Dynamic analysis of a stochastic epidemic model incorporating the double epidemic hypothesis and Crowley-Martin incidence term. Electronic Research Archive, 2023, 31(10): 6134-6159. doi: 10.3934/era.2023312
    [4] Xueyong Zhou, Xiangyun Shi . Stability analysis and backward bifurcation on an SEIQR epidemic model with nonlinear innate immunity. Electronic Research Archive, 2022, 30(9): 3481-3508. doi: 10.3934/era.2022178
    [5] Tao Zhang, Mengjuan Wu, Chunjie Gao, Yingdan Wang, Lei Wang . Probability of disease extinction and outbreak in a stochastic tuberculosis model with fast-slow progression and relapse. Electronic Research Archive, 2023, 31(11): 7104-7124. doi: 10.3934/era.2023360
    [6] Yike Lv, Xinzhu Meng . Evolution of infectious diseases induced by epidemic prevention publicity and interaction between heterogeneous strains. Electronic Research Archive, 2024, 32(8): 4858-4886. doi: 10.3934/era.2024223
    [7] Ting Kang, Qimin Zhang, Qingyun Wang . Nonlinear adaptive control of avian influenza model with slaughter, educational campaigns and treatment. Electronic Research Archive, 2023, 31(8): 4346-4361. doi: 10.3934/era.2023222
    [8] Wenhui Niu, Xinhong Zhang, Daqing Jiang . Dynamics and numerical simulations of a generalized mosquito-borne epidemic model using the Ornstein-Uhlenbeck process: Stability, stationary distribution, and probability density function. Electronic Research Archive, 2024, 32(6): 3777-3818. doi: 10.3934/era.2024172
    [9] Xing Wu, Shuai Mao, Luolin Xiong, Yang Tang . A survey on temporal network dynamics with incomplete data. Electronic Research Archive, 2022, 30(10): 3786-3810. doi: 10.3934/era.2022193
    [10] Xiang Zhang, Tingting Zheng, Yantao Luo, Pengfei Liu . Analysis of a reaction-diffusion AIDS model with media coverage and population heterogeneity. Electronic Research Archive, 2025, 33(1): 513-536. doi: 10.3934/era.2025024
  • Early and successful myocardial reperfusion with primary percutaneous coronary intervention (pPCI) is the optimal therapy for patients presenting with ST segment elevation myocardial infarction (STEMI). Despite successful epicardial reopening of the infarct related artery, myocardial perfusion may not be restored in up to 40-50% of patients. This phenomenon, referred to as no-reflow (NR), recognizes several pathogenetic components including distal atherothrombotic embolization, ischaemic injury, reperfusion damage, intramyocardial hemorrhage and individual susceptibility of coronary microcirculation. However the complexity of pathogenesis remains still unclear. Moreover, cause NR plays a crucial role in patients prognosis, accurate detection is critical and multiple novel diagnostic modalities has been recently assessed.The NR phenomenon represents a challenge in the management of STEMI patients and has recently captured a growing interest of both basic scientists and interventional cardiologists. Although relevant efforts to transfer into real world practice new therapeutic strategies, to date there is still weak evidence of clinical improvement in this setting. Several strategies of prevention and treatment of NR have been proposed in the clinical arena including pharmacological and mechanical interventions. Nevertheless, the complexity of the phenomenon makes extremely unlikely for a single therapy to be effective. Understanding the interaction between the components of this pathway, along with exploring newer and more effective agents may enable patients to be treated with the most appropriate therapy.



    Malaria, a vector-borne disease, instigated by Plasmodium protozoan parasites of female Anopheles mosquitoes, has been a serious threat to human health for ages. According to the reports of WHO, the disease caused nearly 241 million cases and claimed 627, 000 lives worldwide in the year 2020 [1]. In 2019, there were 227 million cases and nearly 69, 000 fewer deaths due to malaria than in 2020 [1]. There are more than 200 known species of Plasmodium parasite which infect humans as well as other vertebrates. Out of these species of Plasmodium parasite, P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi are known to infect humans. The first two of these pose the greatest threat to human populations, and P. knowlesi causes zoonotic malaria that occurs in South-east Asia [2].

    There are almost 3500 known species of mosquitoes, which are grouped into 41 genera. Malaria is transmitted in the human population only by the females of the genus Anopheles. The epicenter of malaria lies in the tropical and subtropical regions of the world, which are the natural breeding sites of Anopheles mosquito populations. The life cycle of Anopheles mosquitoes begins with laying their eggs in stagnant water, which further hatch into larvae and then mature into adult mosquitoes. The male mosquitoes feed upon sources of sugar such as nectar. The females also feed on sources of sugar to meet their energy requirements but require a blood meal to mature their fertilized eggs. During this course the female mosquito may become infected by sucking blood of a malaria-infected individual and becomes a source of transmission of Plasmodium parasites to susceptible individuals. Among 475 species named in the genus Anopheles, only 41 species, such as An. gambiae, An. funestus, etc., have been identified as dominant vectors of human malaria. The remaining either bite humans seldomly or cannot sustain development of malaria parasites. It is also noteworthy that different Anopheles species are responsible for Malaria transmission in different geographic regions[3].

    However, the transmission of Plasmodium parasite through the malarious mosquito requires a viable environment, usually provided by natural as well as household discharges into the atmosphere in residential population areas, so that the life span of the mosquito is enough for the parasite to successfully nurture itself and then be ready to invade the human population. [4,5,6]. Water tanks, ponds, the moist gardens, unplanned drainage of sewage water, poor solid waste disposal, etc. [7] provide conducive environments for fertilization and breeding of the female Anopheles mosquitoes in residential areas, thereby leading to increased malarial contacts with humans [8]. Changes in the environment caused due to deforestation, agricultural activities and urbanization are also seen to have a huge impact on malaria transmission [9].

    It is also seen that the mosquito-borne diseases are directly affected by population density related factors [10]. One of the major factors contributing to malaria transmission is the migration of human population, which may either be long-term migration or short-term movement of persons between locations with low and high malaria burdens. Therefore, it is very important to study the effect of household and other natural discharges on growth of vector population density leading to the spread of vector-borne infectious diseases.

    Mathematical models have long been used to provide a definitive structure for better understanding of the disease-dynamics of malaria. Bailey et al. developed quantitative approaches to study malaria transmission [4]. Thereafter, many other researchers have done modeling and analysis of the dissemination of infectious diseases including malaria [11,12,13,14,15,16]. Singh et al. have conducted mathematical studies of effects of human population related factors on the spread of malaria [17]. Ghosh et al. have proposed an optimal control model of malaria using larvivorous fishes as control measures [18]. Ndamuzi et al. have proposed a deterministic model of malaria transmission in mosquito and human populations in Burundi, an East African country [19]. They have shown that the probabilities of a mosquito being infected and a human being bitten by an infectious mosquito must be reduced by applying optimal control strategies to curb the spread of malaria. Wu et al. have proposed a differential mathematical model to study the effect of time delay on stability of equilibria considering treated and successfully treated classes of human populations [20]. Traoré et al. have shown through a mathematical model that the global behavior of malaria transmission dynamics is dependent strongly on the vector reproduction ratio and basic reproduction ratio [21]. Elaiw et al. have studied a reaction diffusion model of malaria transmission [22]. Noeiaghdam et al. have analyzed several non-linear mathematical models of malaria infection [23,24].

    In most of these models, the density dependent contact rates and the effect of non-emigrating population of the habitat along with parameters concerning natural and household discharges have not been considered in the modeling processes, but in a realistic situation, the contact rates between susceptible and infective populations depend upon non-emigrating and total populations of the human habitat [25,26,27]. Thus, the effect of a variable transmission rate as a function of emigrating population of the habitat should to be studied mathematically. Also, the study of effects of natural as well as anthropogenic discharges on dissemination of the disease needs to be focused on. In this paper, the effects of household and other natural discharges on the growth of the vector population in the environment, leading to the spread of infectious diseases, are studied by considering the density dependent contact rates between susceptible and infective populations as a linear function of total population.

    The following important assumptions are made in the modeling process:

    ● In this paper, we have considered those female Anopheles mosquito species which are able to transmit Plasmodium parasites responsible for human infections in a given region.

    ● The malarial contact rate between the susceptible human population and infected mosquito population is increased with the increase in the density of non-emigrating population of the habitat and decreases as the emigration increases [28,29].

    ● The density of the vector (female Anopheles mosquito) population is assumed to be governed by a logistic model with the intrinsic growth rate as a linear function of the cumulative density of household and other natural discharges [30].

    ● The growth rate of the vector population decreases with a rate which is proportional to the vector population due to natural causes as well as use of pesticides and other control measures.

    ● The growth rate of cumulative density of household and other natural discharges depends on the current population in the habitat. Also, it increases with a constant rate caused by natural factors, but it decreases with a constant rate which is proportional to the cumulative density of household and other natural discharges.

    Let total population density of the human habitat be $ N(t) $, which is divided into two subclasses as susceptible population density $ X(t) $ and infective population density $ Y(t) $ at time $ t $, respectively, so that $ X(t)+Y(t) = N(t) $. The vector (female Anopheles mosquito) population density at time $ t $ is $ N_1(t) $, which is divided into two subclasses $ X_1(t) $ and $ Y_1(t) $, here $ X_1(t) $ represents the susceptible vector population density, and $ Y_1(t) $ denotes the infectious vector population density. $ C(t) $ is cumulative density of household and other natural discharges in the habitat.

    The contact rate between susceptible humans and infectious vectors is assumed to be $ \beta(N) = \beta- \beta_0 (N-N_0) $, where $ N_0 $ is density of the non-emigrating human population of the habitat.

    In view of the above, we propose the following set of non-linear differential equations which governs the dynamics of the model:

    $ dXdt=A{ββ0(NN0)}XY1dX+μYdYdt={ββ0(NN0)}XY1(μ+α+d)YdX1dt={ϕ0+ϕ1(CC0)}N1ϕN12β2X1Y(dm+αm)X1dY1dt=β2X1Y(dm+αm)Y1dCdt=Q0α0C+α1(AdN)
    $
    (2.1)

    where $ X(0) > 0, \; Y(0)\geq 0, \; N(0) > 0, \; X_1(0)\geq 0, \; Y_1(0)\geq 0, \; N_1(0) > 0, \; C(0) > 0. $ The positive constants of model (2.1) are defined as follows:

    $ A $: Immigration of human population.

    $ \beta $: Constant coefficient of interaction due to infective population density.

    $ \beta_0 $: Emigration dependent coefficient of interaction due to infective population density.

    $ \beta_2 $: Coefficient of interaction between infective population density and susceptible vector population.

    $ d $: Natural death rate coefficient of human population

    $ \alpha $: Disease related death rate coefficient of infective human population.

    $ \mu $: Recovery rate coefficient of infectives.

    $ \phi_0 $: Constant intrinsic growth rate coefficient of vector population density.

    $ \phi $: The depletion rate coefficient of vector population density due to competition.

    $ \phi_1 $: The growth rate coefficient of vector population density due to household and other natural discharges.

    $ Q_0 $: Natural house hold discharges.

    $ \alpha_1 $: Rate coefficient of household discharges due to human activities.

    $ \alpha_0 $: The depletion rate of household and other natural discharges.

    $ \alpha_m $: Death rate coefficient of vector population due to pesticides or other preventive measures.

    $ d_m $: Natural death rate coefficient of vector population density.

    For the analysis of mathematical model (2.1), we get an equivalent form by using $ X = N-Y $ and $ X_1 = N_1-Y_1 $ as follows:

    $ dYdt={ββ0(NN0)}(NY)Y1(μ+α+d)Y
    $
    (2.2)
    $ dNdt=AdNαY
    $
    (2.3)
    $ dY1dt=β2(N1Y1)Y(dm+αm)Y1
    $
    (2.4)
    $ dN1dt={ϕ0+ϕ1(CC0)}N1ϕN12(dm+αm)N1
    $
    (2.5)
    $ dCdt=Q0α0C+α1(AdN).
    $
    (2.6)

    with the initial conditions $ Y(0)\geq 0, \; N(0) > 0, \; Y_1(0)\geq 0, \; N_1(0) > 0, \; C(0) > 0. $

    First, to analyze the long term behavior of the model system (2.2)–(2.6), we obtain the region of attraction of solution trajectories. The following lemma provides us the region of attraction, which is required for further analysis of the model system [31].

    Lemma 3.1. The region of attraction for the model system (2.2)–(2.6) is given by the set defined as:

    $ Γ={(Y,N,Y1,N1,C)R+5:0YA(α+d),A(α+d)NAd,0Y1Y1m,0N1N1m,0CCm}
    $

    where $ C_m = C_0+\frac{A\alpha_1 \alpha}{\alpha_0(\alpha+d)} $, $ {N_1}_m = \frac{\phi_1C_0+\phi_0-d_m-\alpha_m}{\phi}+\frac{A\alpha_1 \alpha \phi_1}{\phi \alpha_0(\alpha+d)} $ and $ {Y_1}_m = \frac{\beta_2 A^2}{d(\alpha_m+d_m)(\alpha+d)} $.

    It attracts all the solutions initiating in the interior of the region.

    Theorem 3.2. There are three equilibrium points in the region of attraction for the model system (2.2) –(2.6):

    (i) $ E_0 (0, \frac{A}{d}, 0, 0, C_0), $ the infected human population-free and vector-free equilibrium point. This equilibrium point exists without any condition and represents the complete eradication of malaria along with the vector population.

    (ii) $ E_1(0, \frac{A}{d}, 0, \bar{N_1}, C_0), $ the infective human population free and infectious vector population-free equilibrium point. This disease free equilibrium exists if $ \phi_0-\alpha_m-d_m > 0 $ where $ \bar{N_1} = \frac{\phi_0-\alpha_m-d_m}{\phi} $.

    (iii) $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*), $ non-trivial endemic equilibrium point, provided

    $ R0=(β+β0N0).Adβ2αm+dm.ϕ0αmdmϕ(μ+α+d)+β0.A2d2.β2αm+dmϕ0αmdmϕ>1.
    $
    (3.1)

    Proof. The existence of $ E_0(0, \frac{A}{d}, 0, 0, C_0) $, and $ E_1(0, \frac{A}{d}, 0, \bar{N_1}, C_0) $ are obvious. We prove the existence of $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ from model system (2.2)–(2.6).

    By using $ Y\neq0 $ and $ N_1\neq0, $ we get

    $ {ββ0(NN0)}(NY)Y1(μ+α+d)Y=0
    $
    (3.2)
    $ AdNαY=0
    $
    (3.3)
    $ β2(N1Y1)Y(αm+dm)Y1=0
    $
    (3.4)
    $ ϕ1(CC0)ϕN1+ϕ0(dm+αm)=0
    $
    (3.5)
    $ Q0+α1(AdN)α0C=0.
    $
    (3.6)

    By using Eqs (3.3)–(3.5), we get

    $ N1={β2Y+αm+dm}Y1β2Y.
    $
    (3.7)

    By using (3.2)–(3.7), we define a polynomial function $ F(Y) $.

    $ F(Y)={(β+β0N0β0Ad)β2A(ϕ0αmdm)ϕd(μ+α+d)(αm+dm)}+{(β+β0N0β0Ad)β2A(ϕ1α1α)ϕα0d(μ+α+d)β2}Y{(β+β0N0β0Ad)αα1ϕ1(α+d)α0d2+(ϕ0αmdm)β0α(α+d)ϕd2Aβ0ϕ1α1α2α0ϕd2}β2Y2β0β2α1(α+d)α2α0ϕd2Y3.
    $
    (3.8)

    By using (3.8), we get the followings:

    (i) $ F(0) = \left\{\left(\beta +\beta_0N_0-\beta_0\frac{A}{d}\right)\frac{\beta_2 A(\phi_0-\alpha_m-d_m)}{\phi d}-\left(\mu+\alpha +d\right)(\alpha_m+d_m)\right\} > 0 $, for $ R_0 > 1 $ as defined in (3.1).

    (ii) $ F(\frac{A}{\alpha+d}) = -(\mu+\alpha+d)(\alpha_m+d_m+\frac{\beta_2A}{\alpha +d}) < 0 $.

    Since the function $ F(Y) $ is a polynomial function of degree three in $ Y $, it is continuous and differentiable. Hence, the equation $ F(Y) = 0 $ has at least one root lying in $ 0 < Y < \frac{A}{\alpha+d} $. To show the uniqueness of the root, we prove $ F(Y) $ is monotonic (non-increasing) in $ 0 < Y < \frac{A}{\alpha+d} $, and for this we prove $ F'(Y) < 0 $. By differentiating (3.8) with respect to $ Y $, we get

    $ F(Y)={(β+β0N0β0Ad)β2A(ϕ1α1α)ϕα0d(μ+α+d)β2}{(β+β0N0β0Ad)αα1ϕ1(α+d)α0d2+(ϕ0αmdm)β0α(α+d)ϕd2Aβ0ϕ1α1α2α0ϕd2}β22Yβ0β2α1(α+d)α2α0ϕd23Y2.
    $
    (3.9)

    Then, by using (3.8) again, we have

    $ YF(Y)={(β+β0N0β0Ad)β2A(ϕ0αmdm)ϕd(μ+α+d)(αm+dm)}{(β+β0N0β0Ad)β2A(ϕ1α1α)ϕα0d(μ+α+d)β2}Yβ0β2α1(α+d)α2α0ϕd2Y3.
    $
    (3.10)

    On simplification, we get- $ YF'(Y) < 0 $ for $ R_0 > 1. $ Thus, the polynomial equation $ F(Y) = 0 $ has a unique solution $ Y = Y^* $ in $ 0 < Y < \frac{A}{(\alpha+d)}. $ Now, by using the value of $ Y^* $ the value of $ N^* $ can be determined from (3.3), and the values of other variables can be determined uniquely from Eqs (3.4) to (3.6). Hence, $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ exists if $ R_0 > 1. $

    The results related to stability of the equilibrium points $ E_0(0, \frac{A}{d}, 0, 0, C_0) $, $ E_1(0, \frac{A}{d}, 0, \bar{N_1}, C_0) $ and $ E_2 (Y^*, N^*, Y_1^*, N_1^*, C^*) $ are stated in the following theorems [32].

    Theorem 4.1. The equilibrium point $ E_0 (0, \frac{A}{d}, 0, 0, C_0) $ is unstable when $ \phi_0-\alpha_m-d_m > 0 $, and $ E_1(0, \frac{A}{d}, 0, \bar{N}, C_0) $ is unstable whenever $ R_0 > 1 $. The non-trivial equilibrium $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ is locally asymptotically stable provided the following conditions are satisfied:

    $ αYβ20(NY)2<Nd{β(N)}2
    $
    (4.1)

    and

    $ {(NY)Y2+ϕ2α20Y1(N1Y1)dβ2αα21ϕ21(β2Y+dm+αm)}2<{YY12Nϕ2α20dβ22αα21ϕ21}{β2Y+dm+αm}2
    $

    Proof. From the model system (2.2)–(2.6)

    $ dYdt={ββ0(NN0)}(NY)Y1(μ+α+d)Y
    $
    (4.2)
    $ dNdt=AdNαY
    $
    (4.3)
    $ dY1dt=β2(N1Y1)Y(dm+αm)Y1
    $
    (4.4)
    $ dN1dt={ϕ0+ϕ1(CC0)}N1ϕN12(dm+αm)N1
    $
    (4.5)
    $ dCdt=Q0α0C+α1(AdN)
    $
    (4.6)

    For the model system, we find the Jacobian matrix as follows:

    $ \left[ A11A12A1300αd000β2(N1Y1)0β2Yαmdmβ2Y0000A44ϕ1N10α1d00α0
    \right] $

    where

    $ A11=β(N)Y1(α+d+μ)A12=β(N)Y1β0Y1(NY)A13=β(N)(NY)A44=ϕ0+ϕ1(CC0)2ϕN1αmdm.
    $

    The Jacobian matrix at the equilibrium point $ E_0(0, \frac{A}{d}, 0, 0, C_0) $ is

    $ \left[ (μ+α+d)0β(Ad)Ad00αd00000αmdm00000ϕ0αmdm00α1d00α0
    \right] $

    For the above Jacobian matrix one of the eigenvalues is $ \phi_0-\alpha_m-d_m > 0 $, which is the condition for existence of $ E_1 $. Hence, $ E_0(0, \frac{A}{d}, 0, 0, C_0) $ is unstable whenever $ E_1 $ exists.

    Now, the Jacobian matrix for the equilibrium point $ E_1(0, \frac{A}{d}, 0, \bar{N_1}, C_0), $ is

    $ \left[ (μ+α+d)0β(Ad)Ad00αd000β2¯N10αmdm00000ϕ0αmdm2ϕ¯N1ϕ¯N10α1d00α0
    \right] $

    It is clear from the above matrix that one of the eigenvalues $ AN_0\bar{N_1}\beta_0\beta_2d+A\bar{N_1}\beta \beta_2 d-A^2\beta_0\beta_2\bar{N_1}-d^2(d_m+\alpha_m)(\alpha+d+\mu) $ is positive, as $ R_0 > 1 $. Hence, the equilibrium point $ E_1(\bar{Y}, \bar{N}, 0, \bar{N_1}, C_0) $ is unstable when $ E_2 $ exists.

    Local stability behavior of $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $-

    We study the local stability behavior of $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ by using Lyapunov's direct method. By using the transformations $ Y = Y^*+y, \; \; \; N = N^*+n, \; \; \; Y_1 = Y_1^*+y_1, \; \; \; N_1 = N_1^*+n_1\; \; \; \; C = C^*+c $, we linearize the model system. We consider the positive definite function

    $ V=12y2+k12n2+k22y21+k32n21+k42c2.
    $
    (4.7)

    Differentiating (4.7) with respect to $ t $, we get

    $ ˙V=y˙y+k1n˙n+k2y1˙y1+k3n1˙n1+k4c˙c.
    $
    (4.8)

    We linearise the model system about $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ as follows:

    $ ˙y={Y1β(N)(α+d+μ)}y+{Y1β(N)(NY)β0Y1}n+β(N)(NY)y1
    $
    (4.9)
    $ ˙n=αydn
    $
    (4.10)
    $ ˙y1=β2(N1Y1)y(β2Y+dm+αm)y1+β2Yn1
    $
    (4.11)
    $ ˙n1=ϕN1n1+ϕ1N1c
    $
    (4.12)
    $ ˙c=α1dnα0c.
    $
    (4.13)

    Using the equations from (4.9)–(4.13) in (4.8), we have

    $ ˙V={Y1β(N)(α+d+μ)}y2+{Y1β(N)(NY)β0Y1}ny+β(N)(NY)yy1k1dn2k1αny+k2{β2(N1Y1)yy1(β2Y+dm+αm)y21+β2Yn1y1}+k3{ϕN1n21+ϕ1N1n1c}+k4{α1dcnα0c2}.
    $
    (4.14)

    In (4.14), we choose the constant $ k_1 $ such that $ k_1 = \frac{Y_1^*\beta(N^*)}{\alpha} $, and we get

    $ ˙V={Y1NYβ(N)}y2{β0Y1(NY)}ny+β(N)(NY)yy1k1dn2+k2{β2(N1Y1)yy1(β2Y+dm+αm)y21+β2Yn1y1}+k3{ϕN1n21+ϕ1N1n1c}+k4{α1dcnα0c2}.
    $
    (4.15)

    Rewriting (4.15), we get

    $ ˙V={Y1N2Yβ(N)y2β0Y1(NY)nyY1d2αβ(N)n2}+{Y1N2Yβ(N)y2+{β(N)(NY)+k2β2(N1Y1)}yy1k22(β2Y+dm+αm)y21}+{k32{ϕN1n21}+k2β2Yn1y1k22(β2Y+dm+αm)y21}+{{k32{ϕN1n21}+k3ϕ1N1cn1α0k42c2}+{Y1d2αβ(N)n2k4α1dncα0k42c2}.
    $

    The derivative $ \dot{V} < 0 $ if the inequalities given below are satisfied.

    $ αYβ20(NY)2<Nd{β(N)}2
    $
    (4.16)
    $ Y{β(N)(NY)+k2β2(N1Y1)}2(β2Y+dm+αm)<k2Y1Nβ(N)
    $
    (4.17)
    $ {(k2β2Y}2<k2k3ϕN1(β2Y+dm+αm)
    $
    (4.18)
    $ {k3ϕ1N1}2<k3k4ϕN1α0
    $
    (4.19)
    $ {k4α1d}2<α0k4Y1dαβ(N).
    $
    (4.20)

    By combining inequalities (4.16)–(4.20), we get the conditions stated in Theorem 4.1.

    $ αYβ20(NY)2<Nd{β(N)}2,
    $
    (4.21)

    and

    $ {(NY)Y2+ϕ2α20Y1(N1Y1)dβ2αα21ϕ21(β2Y+dm+αm)}2<{YY12Nϕ2α20dβ22αα21ϕ21}{β2Y+dm+αm}2.
    $

    Theorem 4.2. The equilibrium point $ E_2 (Y^*, N^*, Y_1^*, N_1^*, C^*) $ is non-linearly stable in $ \Gamma $ provided the following two inequalities are satisfied.

    $ αY{Ad.β0Y1m}2<Nd{Y1β(N)}2
    $
    (4.22)
    $ {AdY2+ϕ2α20Y1N1mdβ2αα21ϕ21(β2Y+dm+αm)}2<{YY12Nϕ2α20dβ22αα21ϕ21}{β2Y+dm+αm}2.
    $

    Proof. For non-linear stability, we consider the following positive definite function.

    $ U=12(YY)2+K12(NN)2+K22(Y1Y1)2+K3{N1N1N1lnN1N1}+K42(CC)2.
    $
    (4.23)

    On differentiating (4.23) with respect to $ t $, we get

    $ ˙U=(YY)˙Y+K1(NN)˙N+K2(Y1Y1)˙Y1+K3˙N1N1(N1N1)+K4(CC)˙C.
    $
    (4.24)

    By using model system (2.2)–(2.6), we get

    $ ˙Y=β(N)Y1(NN)+β(N)(NY)(Y1Y1)β0(NY)Y1(NN)β(N)NY1Y(YY)
    $
    (4.25)
    $ ˙N=d(NN)α(YY)
    $
    (4.26)
    $ ˙Y1=β2Y(N1N1)(β2Y+dm+αm)(Y1Y1)+β2(N1Y1)(YY)
    $
    (4.27)
    $ ˙N1=ϕ1(CC)ϕ(N1N1)
    $
    (4.28)
    $ ˙C=dα1(NN)α0(CC).
    $
    (4.29)

    By using (4.25)–(4.29) in (4.24), we get

    $ ˙U=β(N)Y1(NN)(YY)+β(N)(NY)(Y1Y1)(YY)β0(NY)Y1(NN)(YY)β(N)NY1Y(YY)2+K1{d(NN)2α(YY)(NN)}+K2{β2(N1Y1)(YY)(Y1Y1)(β2Y+dm+αm)(Y1Y1)2+β2Y(Y1Y1)(N1N1)}+K3{ϕ1(CC)(N1N1)ϕ(N1N1)2}+K4{dα1(NN)(CC)α0(CC)2}.
    $
    (4.30)

    We choose constant $ K_1 $ such that $ K_1 = \frac{Y_1^*\beta(N^*)}{\alpha} $ and the reduced form of 4.30 is as follows:

    $ ˙U={Y1N2Yβ(N)(YY)2β0Y1(NY)(NN)(YY)dY1β(N)2α(NN)2}+{Y1N2Yβ(N)(YY)2+{β(N)(NY)+K2β2(N1Y1)}(Y1Y1)(YY)K22(β2Y+dm+αm)(Y1Y1)2}+{K32{ϕ(N1N1)2}+K2β2Y(N1N1)(Y1Y1)K22(β2Y+dm+αm)(Y1Y1)2}+{{K32{ϕ(N1N1)2}+K3(CC)(N1N1)α0k42(CC)2}+{dY1β(N)2α(NN)2K4α1d(NN)(CC)α0K42(CC)2}.
    $

    Thus, $ \dot{U} < 0 $ if the following inequalities are satisfied.

    $ αY{β0Y1(NY)}2<Nd{Y1β(N)}2
    $
    (4.31)
    $ {β(N)(NY)+K2β2(N1Y1)}2<K2Y1Nβ(N)Y(β2Y+dm+αm)
    $
    (4.32)
    $ {K2β2Y}2<K2K3ϕ(β2Y+dm+αm)
    $
    (4.33)
    $ {K3ϕ1}2<K3K4ϕα0
    $
    (4.34)
    $ {K4α1d}2<α0K4Y1dαβ(N).
    $
    (4.35)

    By combining conditions (4.32)–(4.35) and using the value of $ K_1 $, we get the conditions stated in Theorem 4.2.

    $ αY{Ad.β0Y1m}2<Nd{Y1β(N)}2,
    $
    (4.36)
    $ {AdY2+ϕ2α20Y1N1mdβ2αα21ϕ21(β2Y+dm+αm)}2<{YY12Nϕ2α20dβ22αα21ϕ21}{β2Y+dm+αm}2.
    $
    (4.37)

    In this section, we illustrate the analytical findings of the model by choosing a set of parameter values. We numerically find the nontrivial endemic equilibrium point $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ and discuss its stability behavior for the parameter values given in Table 1 by using MAPLE.

    Table 1.  List of Parameters along with values.
    Parameter Value of the Parameter
    $ A $ 500 ([30])
    $ d $ 0.03 ([30])
    $ \alpha $ 0.06 ([30])
    $ \beta $ 0.000012 ([30])
    $ \mu $ 0.06
    $ \beta2 $ $ 0.002 $
    $ N_0 $ 10000 ([30])
    $ \phi_0 $ 0.08
    $ \beta_0 $ $ 1.98 \times 10^{-10} $ ([30])
    $ \phi $ 0.0001
    $ \phi_1 $ 0.01
    $ \alpha_1 $ 0.005
    $ \alpha_0 $ 0.048
    $ Q_0 $ 15
    $ C_0 $ 312.5
    $ \alpha_m $ 0.02
    $ d_m $ 0.03

     | Show Table
    DownLoad: CSV

    For these values of parameters, the local and global stability conditions are satisfied. The non-zero equilibrium point $ E_2 (Y^*, N^*, B^*, C^*) $ corresponding to (2.2)–(2.6) is obtained as follows:

    $ Y^*\approx 210, \; \; N^*\approx 16246, \; \; Y_1^*\approx 183, \; \; N_1^*\approx 400, \; \; C^*\approx 313.8. $

    The Jacobian matrix at $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ for the values of parameters given in Table 1 is

    $ \left[ 0.15200.00140.1726000.060.030000.043400.09200.042000000.0370400.00015000.048
    \right] $

    The Eigenvalues corresponding to the Jacobian matrix at the equilibrium point $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ are- [-0.2130, -0.0026, -0.0741, -0.0346+0.0340i, -0.0346-0.0340i]. Since three eigenvalues are negative, and two eigenvalues have negative real part, the equilibrium point $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ is asymptotically stable for this set of values.

    To illustrate the non-linear behavior of the equilibrium point $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*) $ and the effect of various parameters on infected human population $ Y $, the models (2.2)–(2.6) is used to plot Figures 18.

    Figure 1.  Phase plots between infected human population density $ Y(t) $ and total human population density $ N(t) $.
    Figure 2.  Effect of constant coefficient of interaction $ \beta $ due to infectives on infective population density $ Y $.
    Figure 3.  Effect of emigration dependent coefficient of interaction $ \beta_0 $ due to infectives on infective population density $ Y $.
    Figure 4.  Effect of Constant coefficient of interaction $ \beta_2 $ among the vector population density on infective population density $ Y $.
    Figure 5.  The effect of growth rate coefficient $ \phi_1 $ of vector population density due to household and other natural discharges on infective population density $ Y $.
    Figure 6.  Effect of constant intrinsic growth rate coefficient $ \phi_0 $ of vector population density on infective population density $ Y $.
    Figure 7.  Effect of non-emigrating population density of human habitat $ N_0 $ on infective population density $ Y $.
    Figure 8.  Effect of constant immigration $ A $ on infective population density $ Y $.

    Figure 1 shows that the trajectories initiating from different initial conditions are convergent to the equilibrium point $ E_2(Y^*, N^*, Y_1^*, N_1^*, C^*), $ which indicates the global stability of equilibrium point $ E_2(Y^*, N^*, Y_1^*, $ $ N_1^*, C^*) $. In this figure, we have plotted four curves with different colors, each curve initiating from a different point, i.e., initial condition. All these curves approach the equilibrium point as the time progresses. Here, the curves with red, black, green and blue colors correspond to the initial condions ($ C(0) = 312.51, N_1(0) = 500, N(0) = 10000, Y_1(0) = 100, Y(0) = 700 $), ($ C(0) = 312.51, N_1 (0) = 500, N (0) = 15000, Y_1 (0) = 100, Y(0) = 1000 $), ($ C(0) = 312.51, N_1 (0) = 500, N (0) = 20000, Y_1 (0) = 100, Y(0) = 50 $) and ($ C(0) = 312.51, N_1 (0) = 500, N (0) = 8000, Y_1 (0) = 100, Y(0) = 50 $), respectively, which are all converging at $ E_2 $. From Figure 2 we see that with the increase in the constant rate of contact between susceptible humans and infected vectors, infective human population of the habitat increases. By Figure 3, it can be seen that as emigration dependent contact rate between susceptibles and infectives increases, the infective population density of the habitat decreases. Figure 4 shows that as the constant rate of contact between susceptible and infective vector population increases, the infected humans in the habitat are increased. From Figure 5, it is noted that as growth rate coefficient due to household and other natural discharges increases, the total vector population of the habitat and infected human population density of the habitat also increase. By Figure 6, it is also observed that with the increase in constant intrinsic growth rate coefficient of vector population density, the infectives of the habitat are increased. By Figure 7 it is observed that the non-emigrating population of the habitat also has a positive effect on the infected human population. In Figure 8, the effect of increase in the constant immigration rate on the infected population density is observed.

    In this section, we conduct the basic differential sensitivity analysis of the model system (2.2)–(2.6) for the parameters $ \beta, \beta_2, \phi_0, \phi_1 $ following Bortz and Nelson [33]. This is quite useful for the comparative study of impacts of changes in these parameters on the behavior of the model system. For instance, the sensitivity systems with respect to parameter $ \beta $ is as follows:

    $ ˙Yβ(t,β)={1β0Nβ(t,β)}(N(t,β)Y(t,β))Y1(t,β)+{ββ0(N(t,β)N0)}(N(t,β)Y(t,β)}Y1β(t,β)+{ββ0(N(t,β)N0)}(Nβ(t,β)Yβ(t,β))Y1(t,β)(μ+α+d)Yβ(t,β)˙Nβ(t,β)=dNβ(t,β)αYβ(t,β)˙Y1β(t,β)=β2(N1β(t,β)Y1β(t,β))Y(t,β)+β2(N1(t,β)Y1(t,β))Yβ(t,β)(dm+αm)Y1β(t,β)˙N1β(t,β)=(ϕ1Cβ(t,β))N1(t,β)+(ϕ0+ϕ1(C(t,β)C0))N1β(t,β)2ϕN1(t,β)N1β(t,β)(dm+αm)N1β(t,β)˙Cβ(t,β)=α0Cβ(t,β)+α1(dNβ(t,β))
    $

    Here, $ Y_w(t, w) $ represents the sensitivity function of Y with respect to the corresponding parameter w. In Figures 9 to 12, we have plotted semi-relative sensitivity solutions to show the impacts of doubling of parameters $ \beta, \beta_2, \phi_0, \phi_1 $ respectively on variables of the model system (2.2)–(2.6) following Bortz and Nelson [33].

    Figure 9.  Semi-relative sensitivity solutions for the state variables corresponding to infected human population with respect to parameters $ \beta, \beta_2, \phi_0, \phi_1 $.
    Figure 10.  Semi-relative sensitivity solutions for the state variables corresponding to total human population with respect to parameters $ \beta, \beta_2, \phi_0, \phi_1 $.
    Figure 11.  Semi-relative sensitivity solutions for the state variables corresponding to infected vector population with respect to parameters $ \beta, \beta_2, \phi_0, \phi_1 $.
    Figure 12.  Semi-relative sensitivity solutions for the state variables corresponding to total vector population with respect to parameters $ \beta, \beta_2, \phi_0, \phi_1 $.

    From Figures 9 and 10, it is evident that the parameters $ \phi_0, \beta, \phi_1 $ have significant influence over the infected and total human population densities. From Figure 9, we see that on doubling the intrinsic growth rate of the vector population, there will be a sharp increase of 1725 in the infected human population of the habitat in 200 years. We also see from this figure that doubling the constant coefficient of interaction between susceptible humans and infected vectors causes an increase of 981 cases in the infected population. The doubling of growth rate coefficient of vectors due to various discharges causes an increase of 409 infectives in the considered human habitat in 200 years. From Figure 10, we observe the adverse effects of doubling of the same parameters on total human population. For instance, we see that doubling of growth rate of vectors due to discharges causes a decrease of 630 in the total human population of the habitat. Similar trends are observed in Figures 11 and 12 for vector population density.

    Natural and household discharges such as water tanks, ponds, unplanned disposal of solid wastes, etc., provide a favorable environments for growth of various vectors and vector dependent infectious diseases. Changes in the demography of the region due to immigration and emigration are also among the root causes behind the spread of vector-borne diseases, including malaria. Due to these reasons, despite considerable advancements in medical research in recent decades, malaria continues to be among the leading killers in the twenty-first century.

    In this paper, a non-linear epidemic model has been proposed and analyzed to study the effects of household discharges on the spread of malarious mosquito populations, further causing spread of malaria in human populations. The rates of contact have been assumed to be density dependent. In the model, we have considered five time dependent variables, namely, the susceptible population density $ X(t) $, the infective population density $ Y(t) $, the susceptible vector population density $ X_1(t) $, infective vector population density $ Y_1(t) $ and the cumulative density of household and other natural discharges $ C(t) $. The variable contact rate between susceptibles and infectives is considered to be emigration dependent. The growth of the vector population in the habitat has been considered to follow a logistic model, the intrinsic growth rate of which depends linearly on the infective population density as well as on the cumulative density of household and other natural discharges.

    We have obtained three equilibrium states of the model. Two of the equilibrium points are free of infective human and vector populations. One of these two ($ E_0 $) is completely vector free, and the other ($ E_1 $) has a non-zero equilibrium value of susceptible vector population but is infectious vector-free. An important relation among growth rate and depletion rate coefficients of vector population is obtained for the existence of $ E_1 $. From the stability analysis, it is found that $ E_0 $ is unstable whenever $ E_1 $ exists. The third equilibrium $ E_2 $ is a non-trivial endemic equilibrium which exists if $ R_0 > 1 $. The quantity $ R_0 $ depends on various system parameters. If we decrease $ \beta, \beta_0, $ and $ N_0 $ then $ R_0 $ also decreases and if we restrict $ R_0 $ to be less than 1, we get only disease free equilibrium points. From stability analysis, we observe that $ E_1 $ is unstable whenever $ E_2 $ exists. The local and global stability conditions for $ E_2 $ are obtained by using Lyapunov's stability method. These stability conditions show that the disease related death rate, the rate of household discharges, the growth rate of vectors due the various discharges and emigration dependent coefficient of interaction have destabilizing effects on the system at $ E_2 $.

    The numerical simulation is done to illustrate the model findings. The simulation of the epidemic model shows that the spread of vector dependent infectious diseases increases as the density of cumulative household and other natural discharges increases. It is shown further that the infective population density decreases as emigrating population of the habitat increases. If the non-emigrating population density of the habitat increases, the interaction between populations of the habitat increases, i.e., infective population density increases. To examine the sensitivity of model solutions with respect to the key parameters, a basic differential sensitivity analysis is also performed. The simulation study of the model has confirmed the obtained analytical results.

    Sunil Sharma is thankful to the Deanship of Scientific Research at Majmaah University for supporting this work under project no. R-2022-334. The authors are grateful to the handling editor and the anonymous reviewers for their valuable suggestions, which helped in improving the quality of the paper.

    The authors declare no conflict of interest.

    [1] Hamm CW, Bassand JP, Agewall S, et al. (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. Eur Heart J 32: 2999-3054. doi: 10.1093/eurheartj/ehr236
    [2] Rezkalla SH, Kloner RA (2008) Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 72: 950-957. doi: 10.1002/ccd.21715
    [3] Eeckhout E, Kern MJ (2001) The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 22: 729-739 doi: 10.1053/euhj.2000.2172
    [4] Wu KC, Zerhouni EA, Judd RM, et al. (1998) Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97: 765-772. doi: 10.1161/01.CIR.97.8.765
    [5] Brosh D, Assali AR, Mager A, et al. (2007) Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 99: 442-445. doi: 10.1016/j.amjcard.2006.08.054
    [6] Bolognese L, Carrabba N, Parodi G, et al. (2004) Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109: 1121-1126. doi: 10.1161/01.CIR.0000118496.44135.A7
    [7] Ndrepepa G, Tiroch K, Fusaro M, et al. (2010) A 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55: 2383-2389. doi: 10.1016/j.jacc.2009.12.054
    [8] Kloner RA, Ganote CE, Jennings RB (1974) The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54: 1496-1508. doi: 10.1172/JCI107898
    [9] Galiuto L, Lombardo A, Maseri A, et al. (2003) Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 89: 731-737. doi: 10.1136/heart.89.7.731
    [10] Limbruno U, De CM, Pistolesi S, et al. (2005) Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J 150: 102-108 doi: 10.1016/j.ahj.2005.01.016
    [11] Bahrmann P, Werner GS, Heusch G, et al. (2007) Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 115: 600-608 doi: 10.1161/CIRCULATIONAHA.106.660779
    [12] Kleinbongard P, Bose D, Baars T, et al. (2011) Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 108: 344-352 doi: 10.1161/CIRCRESAHA.110.235713
    [13] Tranum-Jensen J, Janse MJ, Fiolet WT, et al. (1981) Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine. Circ Res 49: 364-381. doi: 10.1161/01.RES.49.2.364
    [14] Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121-1135. doi: 10.1056/NEJMra071667
    [15] Paradies G, Petrosillo G, Pistolese M, et al. (2004) Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin. Circ Res 94: 53-59. doi: 10.1161/01.RES.0000109416.56608.64
    [16] Petrosillo G, Di Venosa N, Moro N, et al. (2011) In vivo hyperoxic preconditioning protects against rat-heart ischemia/reperfusion injury by inhibiting mitochondrial permeability transition pore opening and cytochrome c release. Free Radic Biol Med 50: 477-483. doi: 10.1016/j.freeradbiomed.2010.11.030
    [17] Lefer AM, Tsao PS, Aoki N, et al. (1990) Mediation of cardioprotection by transforming growth factor-beta. Science 249: 61-64. doi: 10.1126/science.2164258
    [18] Furuichi K, Wada T, Iwata Y, et al. (2006) Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit Care Med 34: 2447-2455. doi: 10.1097/01.CCM.0000233878.36340.10
    [19] Basso C, Rizzo S, Thiene G (2010) The metamorphosis of myocardial infarction following coronary recanalization. Cardiovasc Pathol 19: 22-28. doi: 10.1016/j.carpath.2009.06.010
    [20] Collet JP, Montalescot G (2005) The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diabetes Vasc Dis Res 2: 136-143. doi: 10.3132/dvdr.2005.021
    [21] Golino P, Maroko PR, Carew TE (1987) The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation 75: 292-298. doi: 10.1161/01.CIR.75.1.292
    [22] Ishihara M (2012) Acute hyperglycemia in patients with acute myocardial infarction. Cric J 76: 563-571.
    [23] Gibson CM, Ryan KA, Murphy SA, et al. (1998) Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol 34: 974-982.
    [24] Araszkiewicz A, Lesiak M, Grajek S, et al. (2007) Effect of microvascular reperfusion on prognosis and left ventricular function in anterior wall myocardial infarction treated with primary angioplasty. Int J Cardiol 114: 183-187. doi: 10.1016/j.ijcard.2006.01.057
    [25] Lepper W, Sieswerda GT, Vanoverschelde JL, et al. (2001) Predictive value of markers of myocardial reperfusion in acute myocardial infarction for follow-up left ventricular function. Am J Cardiol 88: 1358-1363. doi: 10.1016/S0002-9149(01)02113-0
    [26] Vicente J, Mewton N, Croisille P, et al. (2009) Comparison of the angiographic myocardial blush grade with delayed-enhanced cardiac magnetic resonance for the assessment of microvascular obstruction in acute myocardial infarctions. Catheter Cardiovasc Interv 74: 1000-1007. doi: 10.1002/ccd.22157
    [27] Uetani T, Amano T, Kumagai S, et al. (2009) Intracoronary electrocardiogram recording with a bare-wire system: perioperative ST-segment elevation in the intracoronary electrocardiogram is associated with myocardial injury after elective coronary stent implantation. JACC Cardiovasc Interv 2: 127-135. doi: 10.1016/j.jcin.2008.07.010
    [28] Mather AN, Fairbairn TA, Artis NJ, et al. (2011) Timing of cardiovascular MR imaging after acute myocardial infarction: effect on estimates of infarct characteristics and prediction of late ventricular remodeling. Radiology 261: 116-126. doi: 10.1148/radiol.11110228
    [29] Lund GK, Stork A, Saeed M, et al. (2004) Acute myocardial infarction: evaluation with first-pass enhancement and delayed enhancement MR imaging compared with 201Tl SPECT imaging. Radiology 232: 49-57. doi: 10.1148/radiol.2321031127
    [30] Nijveldt R, Beek AM, Hirsch A, et al. (2008) Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol 52: 181-189. doi: 10.1016/j.jacc.2008.04.006
    [31] Greaves K, Dixon SR, Fejka M, et al. (2003) Myocardial contrast echocardiography is superior to other known modalities for assessing myocardial reperfusion after acute myocardial infarction. Heart 89: 139-144. doi: 10.1136/heart.89.2.139
    [32] Tanaka A, Kawarabayashi T, Nishibori Y, et al. (2002) No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105: 2148-2152. doi: 10.1161/01.CIR.0000015697.59592.07
    [33] Watanabe T, Nanto S, Uematsu M, et al. (2003) Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction: intravascular ultrasound findings. Circ J 67: 667-671. doi: 10.1253/circj.67.667
    [34] Wu X, Mintz GS, Xu K, et al. (2011) The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 4: 495-502.
    [35] Tanaka A, Imanishi T, Kitabata H, et al. (2009) Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. Eur Heart J 30: 1348-1355. doi: 10.1093/eurheartj/ehp122
    [36] Svilaas T, Vlaar PJ, van der Horst IC, et al. (2008) Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358: 557-567. doi: 10.1056/NEJMoa0706416
    [37] Frobert O, Lagerqvist B, Olivecrona GK, et al. (2013) TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369: 1587-1597.
    [38] Jolly SS, Cairns JA, Yusuf S, et al. (2015) TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372: 1389-1398.
    [39] Puymirat E, Aissaoui N, Cottin Y, et al. (2014) Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). Am J Cardiol 114: 1651-1657. doi: 10.1016/j.amjcard.2014.08.039
    [40] Kilic S, Ottervanger JP, Dambrink JH, et al. (2014) Myocardial Infarction Study Group. The effect of thrombus aspiration during primary percutaneous coronary intervention on clinical outcome in daily clinical practice. Thromb Haemost 111: 165-171.
    [41] Jones DA, Rathod KS, Gallagher S, et al. (2015) Manual thrombus aspiration is not associated with reduced mortality in patients treated with primary percutaneous coronary intervention: an observational study of 10,929 patients with ST-segment elevation myocardial infarction from the London Heart Attack Group. JACC Cardiovasc Interv 8: 575-584. doi: 10.1016/j.jcin.2014.11.021
    [42] Siudak Z, Mielecki W, Dziewierz A, et al. (2015) No long-term clinical benefit from manual aspiration thrombectomy in ST-elevation myocardial infarction patients. Data from NRDES registry. Catheter Cardiovasc Interv 85: E16-E22. doi: 10.1002/ccd.25572
    [43] De Rosa S, Cirillo P, De Luca G, et al. (2007) Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction. J Interv Cardiol 20: 292-298. doi: 10.1111/j.1540-8183.2007.00271.x
    [44] Mehta SK, Frutkin AD, Milford-Beland S, et al. (2007) Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol 100: 1114-1118. doi: 10.1016/j.amjcard.2007.04.058
    [45] Baim DS, Wahr D, George B, et al. (2002) Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105: 1285-1290.
    [46] Heusch G, Kleinbongard P, Bose D, et al. (2009) Coronary microembolization: from bedside to bench and back to bedside. Circulation 120: 1822-1836. doi: 10.1161/CIRCULATIONAHA.109.888784
    [47] Ali A, Cox D, Dib N, et al. (2006) Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 48: 244-252. doi: 10.1016/j.jacc.2006.03.044
    [48] Stone GW, Abizaid A, Silber S, et al. (2012) Prospective, randomized,multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the master trial. J Am Coll Cardiol S0735-1097: 04506-8.
    [49] Dudek D, Brener SJ, Rakowski T, et al. (2014) Efficacy of an embolic protection stent as a function of delay to reperfusion in st-segment elevation myocardial infarction (from the MASTER Trial). Am J Cardiol 114: 1485-1489. doi: 10.1016/j.amjcard.2014.08.007
    [50] Thiele H, Schindler K, Friedenberger J, et al. (2008) Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118: 49-57. doi: 10.1161/CIRCULATIONAHA.107.747642
    [51] Bartorelli AL, Trabattoni D, Galli S, et al. (1999) Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 48: 211-213. doi: 10.1002/(SICI)1522-726X(199910)48:2<211::AID-CCD20>3.0.CO;2-V
    [52] Kakkar AK, Moustapha A, Hanley HG, et al. (2004) Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 61: 31-34.
    [53] Stone GW, Maehara A, Witzenbichler B, et al. (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307: 1817-1826. doi: 10.1001/jama.2012.421
    [54] Thiele H, Wohrle J, Hambrecht R, et al. (2012) Intracoronary vs. intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379: 923-931.
    [55] De Rosa S, Caiazzo G, Torella D, et al. (2012) Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials. Int J Cardiol 7-5273(12)01631-2.
    [56] Van't Hof AW, Ten Berg J, Heestermans T, et al. (2008) Ongoing Tirofiban in myocardial infarction evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372: 537-546.
    [57] Authors/Task Force members, Windecker S, Kolh P, Alfonso F, et al. (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35: 2541-2619. doi: 10.1093/eurheartj/ehu278
    [58] Morikawa S, Takabe W, Mataki C, et al. (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178-183. doi: 10.5551/jat.9.178
    [59] Oduncu V, Tanalp AC, Erkol A, et al. (2011) Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 107: 179-185. doi: 10.1016/j.amjcard.2010.09.008
    [60] Iwakura K, Ito H, Kawano S, et al. (2006) Chronic pretreatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 27: 534-539. doi: 10.1093/eurheartj/ehi715
    [61] Lyu T, Zhao Y, Zhang T, et al. (2013) Effect of statin pretreatment on myocardial perfusion in patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. Clin Cardiol 36: E17-24. doi: 10.1002/clc.22169
    [62] Navarese EP, Kowalewski M, Andreotti F, et al. (2014) Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 113: 1753-1764. doi: 10.1016/j.amjcard.2014.02.034
    [63] Ross AM, Gibbons RJ, Stone GW, et al. (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45: 1775-1780. doi: 10.1016/j.jacc.2005.02.061
    [64] Niccoli G, Rigattieri S, De Vita MR, et al. (2013) Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv 6: 580-589. doi: 10.1016/j.jcin.2013.02.009
    [65] Nazir SA, Khan JN, Mahmoud IZ, et al. (2014) The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.Trials 15: 371. doi: 10.1186/1745-6215-15-371
    [66] Ishii H, Ichimiya S, Kanashiro M, et al. (2005) Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST segment-elevation myocardial infarction. Circulation 112: 1284-1288. doi: 10.1161/CIRCULATIONAHA.104.530329
    [67] Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. (2006) Prospective, randomized controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 92: 1278-1284. doi: 10.1136/hrt.2005.075077
    [68] Michaels AD, Appleby M, Otten MH, et al. (2002) Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 14: 299-302.
    [69] Su Q, Li L, Liu Y (2013) Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol 36: E11-16. doi: 10.1002/clc.22143
    [70] Piot C, Croisille P, Staat P, et al (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481. doi: 10.1056/NEJMoa071142
    [71] Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. (2007) A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty TheMelatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 28: 532-539. doi: 10.1016/j.cct.2006.10.007
    [72] Kloner RA, Hale SL, Dai W, et al. (2012) Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide. J Am Heart Assoc 1: e001644.
    [73] Kandzari DE, Hasselblad V, Tcheng JE, et al (2004) Improved clinical outcome with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 147: 457-462. doi: 10.1016/j.ahj.2003.08.011
    [74] Amit G, Cafri C, Yaroslavtsev S, et al. (2006) Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 152: 887.e9-14.
  • This article has been cited by:

    1. ChungYuen Khew, Rahmad Akbar, Norfarhan Mohd-Assaad, Progress and challenges for the application of machine learning for neglected tropical diseases, 2023, 12, 2046-1402, 287, 10.12688/f1000research.129064.1
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6622) PDF downloads(1113) Cited by(0)

Figures and Tables

Figures(5)  /  Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog